NKGen BiotechNKGN
About: NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
Employees: 63
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
12% more funds holding
Funds holding: 17 [Q2] → 19 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.16% less ownership
Funds ownership: 13.73% [Q2] → 10.57% (-3.16%) [Q3]
71% less capital invested
Capital invested by funds: $4.24M [Q2] → $1.23M (-$3.01M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for NKGN.
